- Syngeneic tumor mouse models are established with murine cancer cell lines in immuno-competent mice. Syngeneic mouse models are excellent for studying new anti-cancer therapeutic agents in the presence of a functional immune system. C3H, C57Bl/6J, or C57Bl/6N mice strains are used to establish the syngeneic model.
- Xenograft tumor models are set up with human cancer cells inoculated in athymic (nude) or severe combined immune deficient (SCID) mice. The model can be delivered as a subcutaneous or orthotopic xenograft tumor. Xenograft models allow assessing the efficacy of a drug or therapy specifically against human cancer cells. CD1-Foxn1nu and SCID/beige are in-house, and other mouse strains are on-demand.Service details: A standard study design includes 7 days of acclimatization period, 5-15 days of subcutaneous tumor growth, a study-specific treatment period, and post-treatment observation. Tumor size measurements are usually initiated on day 3-5 post-cancer cells inoculation and monitored daily using a caliper. A study design includes a minimum of 2 groups of mice (tumor-bearing vehicle-treated, and tumor-bearing compound-treated group), 10-15 mice per group. Drug administration can be performed either via invasive (by IV, IP, SC, and IM routes), or noninvasive (PO, IN, or with food/drink) routes. Other specific types of treatment are also possible, for example, photodynamic therapy (PDT) using a wide range of irradiation wavelengths.
Tumor treatment procedures include invasive (by IV, IP, SC, and PO routes), noninvasive (with food) routes of drug administration, as well photodynamic therapy (PDT) using a wide range of irradiation wavelengths.
Sample Submission: Dry compound or compound in pre-made dosing formulation (amount required depends on the dosing levels and schedules). For example, for treating a group of 8 mice at 10 mg/kg, twice daily (b.i.d.) for 1 week, about 16 mg of the test compound is required.